Related Experiment Videos
Thromboxane antagonism and cough in chronic bronchitis
Yoshihisa Ishiura1, Masaki Fujimura, Chihiro Yamamori
1The Division of Pulmonary Medicine, Wajima Municipal Hospital, Wajima, Japan. ishiura-@p2322.nsk.ne.jp
Annals of Medicine
|June 11, 2003
Summary
Thromboxane A2 (TxA2) antagonism, but not cysteinyl leukotrienes (cLTs) antagonism, improved airway cough sensitivity in chronic bronchitis patients. TxA2 antagonism is a potential treatment for chronic productive cough.
Area of Science:
- Respiratory Medicine
- Pharmacology
Background:
- Increased eicosanoid synthesis is implicated in chronic productive cough in chronic bronchitis.
- Airway inflammation and hyperresponsiveness contribute to cough in chronic bronchitis.
Purpose of the Study:
- To investigate the role of thromboxane A2 (TxA2) and cysteinyl leukotrienes (cLTs) in airway cough sensitivity.
- To evaluate the efficacy of TxA2 and cLTs receptor antagonists in patients with stable chronic bronchitis.
Main Methods:
- A randomized, placebo-controlled study involving 16 patients with stable chronic bronchitis.
- Assessed the effects of seratrodast (TxA2 receptor antagonist) and pranlukast (cLTs receptor antagonist) on cough response to inhaled capsaicin.
- Measured the capsaicin cough threshold as an index of airway cough sensitivity.
Main Results:
- Four-week treatment with seratrodast significantly increased the capsaicin cough threshold compared to placebo.
- Pranlukast treatment did not significantly alter the capsaicin cough threshold.
- These findings suggest a specific role for TxA2 in modulating cough sensitivity.
Conclusions:
- Thromboxane A2 (TxA2), rather than cLTs, appears to be a key modulator of airway cough sensitivity in chronic bronchitis.
- Thromboxane antagonism represents a promising therapeutic strategy for managing chronic productive cough.